DF Dent & Co. Inc. Sells 7,515 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

DF Dent & Co. Inc. decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 112,530 shares of the medical research company's stock after selling 7,515 shares during the period. DF Dent & Co. Inc. owned about 0.22% of Charles River Laboratories International worth $20,773,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc boosted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $59,000. Finally, Huntington National Bank raised its position in shares of Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares during the period. 98.91% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

CRL stock traded down $2.12 during trading on Tuesday, reaching $131.95. 488,453 shares of the stock were exchanged, compared to its average volume of 775,423. Charles River Laboratories International, Inc. has a twelve month low of $128.03 and a twelve month high of $258.56. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $6.75 billion, a P/E ratio of 876.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The stock has a 50 day simple moving average of $161.85 and a 200-day simple moving average of $180.06.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. During the same period in the previous year, the business posted $2.46 earnings per share. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the subject of several analyst reports. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Finally, UBS Group reissued a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).